Yellow Fever (Healthy Volunteers) Clinical Trial
Official title:
Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults
The primary objective of the study is to demonstrate the non-inferiority of the antibody response in terms of seroconversion rate 28 days after vaccine administration of one dose of yellow fever vaccine (vYF) compared to the antibody response after one dose of the YF-VAX control vaccine in yellow fever naïve participants. The secondary objectives of the study are: - To describe the immune response to yellow fever in both vaccine groups before and after vYF or YF-VAX administration. - To describe the safety profile of vYF vaccine in comparison to the safety profile of the control YF-VAX. - To describe the biosafety profile of vYF in comparison to the biosafety profile of the control YF-VAX.
The duration of each participant's participation will be approximately 5 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04142086 -
Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults
|
Phase 1 |